Ratifi English Iniciar sesión
Ratifi

Proyectos federales de Congress.gov. Proyectos estatales de Open States.

HB 2410Sesión 2025

Qué cambió entre versiones

54 párrafos cambiaron+1186 palabras agregadas−393 eliminadas

El texto resaltado se agregó en la versión más reciente. El texto tachado se eliminó.

WEST virginia legislature

2025 regular session

Committee Substitute

for

WEST VIRGINIA LEGISLATURE

2025 REGULAR SESSION

Introduced

House Bill 2410

By Delegates Hornby, Chiarelli, Horst, Crouse, Maynor, Willis, and Ward

[OriginatingIntroduced inFebruary 17, 2025; referred to the Standing Committee on Health and Human Resources; Reportedthen onthe March 24, 2025Judiciary]

A BILL to amend and reenact §16-51-1 of the Code of West Virginia, 1931, as amended, relating to the right to try individualized treatments; and defining terms.

A BILL to amend the Code of West Virginia, 1931, as amended by adding a new article, designated §16-51A-1, §16-51A-2, §16-51A-3, §16-51A-4, §16-51A-5, §16-51A-6, §16-51A-7, and §16-51A-8, relating to the right to try individualized treatments; defining terms; defining access to individualized treatments; providing restrictions on outstanding debt related to individualized treatments in the event of death; prohibiting sanctions against licensed healthcare providers; prohibiting specified persons from blocking access to individualized treatments; prohibiting private right of action; providing that the article is not to be construed to affect a health benefit plan's obligation to provide coverage for an insured's participation in a clinical trial; and setting forth effective date.

Be it enacted by the Legislature of West Virginia:

Article 5151A. Right-to-Try ACTIndividualized Treatments.

§16-51-316-51A-1. Definitions.

For the purposes of this article:

The following definitions apply in this article, unless the context requires otherwise:

(1) Eligible facility. – Any institution operating under Federal-wide Assurance for the Protection of Human Subjects in accordance with 45 C.F.R. § 46 and 42 U.S.C. § 289(a).

(12) “Eligible patient”. means– aAn personindividual who hasmeets all of the following criteria:

(Aa) AHas terminal illness attested to by the patient’s treating physician; Aa life-threatening or severely debilitating illness, attested to by a treating physician.

(Bb) ConsideredHas, in consultation with a treating physician, considered all other treatment options currently approved by the United States Food and Drug Administration;.

(C) Been unable to participate in a clinical trial for the terminal illness within one hundred miles of the patient’s home address for the terminal illness, or not been accepted to the clinical trial within one week of completion of the clinical trial application process;

(Dc) ReceivedHas received a recommendation from histhe or hertreating physician for use of an individualized investigational drug, biological product, or device; for treatment of the life-threatening or severely debilitating illness.

(Ed) (D)Has Given written,given informed consent forin thewriting to use of the individualized investigational drug, biological product, or device for treatment of the life-threatening or severely debilitating illness or, if the patientindividual is a minor or lacksis theotherwise mentalincapable capacityof to provideproviding informed consent, athe parent or legal guardian has given written, informed consent onin writing to use of the patient’sindividualized behalf;investigational anddrug, biological product, or device.

(F) (E) Documentation from his or her physician that he or she meets the requirements of this subdivision.

(2) “Eligible patient” does not include a person being treated as an inpatient in a hospital licensed or certified pursuant to §16-5B- et seq.

(e) Has documentation from the treating physician that the individual meets all of the criteria for this definition. This documentation shall include an attestation from the treating physician that the treating physician was consulted in the creation of the written, informed consent required under this article.

(3) “InvestigationalIndividualized investigational drug, biological product, or device”. means– a drug, biological product or device that has successfully completed phase one of a clinical trial but has not yet been approved for general use by the United States Food and Drug Administration or aA drug, biological product, or device that is unique and produced exclusively for use for an individual patient, based on their own genetic profile, including individualized gene therapy antisense oligonucleotides and individualized neoantigen vaccines.

(4) Institution. – As defined in 45 C.F.R. § 46.102(f).

(45) “Terminal illness” means a disease that, without life-sustaining procedures, will soon result in death or a state of permanent unconsciousness from which recovery is unlikely. Life-threatening or severely debilitating illness. means– asAs those terms are defined in 21 C.F.R. § 312.81.

(56) “Written, informed consent”. means– aA written document that is signed by an eligible patient; or if the patient andis attesteda minor, by a parent or legal guardian; or if the patient is incapacitated, by a designated health care agent pursuant to by the patient’s physician and a witnesshealth care power of attorney, that, at a minimum includes all of the following:

(A) ExplainsAn explanation of the currently approved products and treatments for the diseaseeligible patient's life-threatening or conditionseverely fromdebilitating which the patient suffers;illness.

(B) AttestsAn to the factattestation that the eligible patient concurs with histhe or hertreating physician in believing that all currently approved and conventionally recognized treatments are unlikely to prolong the patient’seligible patient's life;.

(C) ClearlyClear identifiesidentification of the specific proposedindividualized investigational drug, biological product, or device thatproposed for treatment of the patienteligible ispatient's seekingterminal to use;illness.

(D) DescribesA description of the potentially best and worst outcomes resulting from use of usingthe theindividualized investigational drug, biological product, or device to treat the eligible patient's life-threatening or severely debilitating illness, along with a realistic description of the most likely outcome,. includingThe thedescription possibility that new, unanticipated, different or worse symptoms might result and that death couldshall be hastened by the proposed treatment based on the physician’streating physician's knowledge of the proposed treatment in conjunction with an awareness of the patient’seligible condition;patient's life-threatening or severely debilitating illness and shall include a statement acknowledging that new, unanticipated, different, or worse symptoms might result from, and that death could be hastened by, the proposed treatment.

(E) A statement that eligibility for hospice care may be withdrawn if the eligible patient begins treatment of the life-threatening or severely debilitating illness with an individualized investigational drug, biological product, or device and that hospice care may be reinstated if such treatment ends and the eligible patient meets hospice eligibility requirements.

(EF) MakesA clearstatement that the patient’seligible patient's health insurerbenefit plan or third-party administrator and provider mayare not be obligated to pay for any care or treatments consequent to the use of the individualized investigational drug, biological product, or device;, unless specifically required to do so by law or contract.

(F) Makes clear that the patient’s eligibility for hospice care may be withdrawn if the patient begins curative treatment and care may be reinstated if the curative treatment ends and the patient meets hospice eligibility requirements;

(G) Makes clear that in-home health care may be denied if treatment begins; and

(HG) StatesA statement that the eligible patient understands that he or she may beis liable for all expenses consequent to the use of the individualized investigational drug, biological product, or device, and that this liability extends to the patient’seligible patient's estate, unless a contract between the patient and the manufacturer of the drug, biological product, or device states otherwise.

(H) A statement that the eligible patient or, for an eligible patient who is a minor or lacks capacity to provide informed consent, that the parent or legal guardian consents to the use of the individualized investigational drug, biological product, or device for treatment of the life-threatening or severely debilitating illness.

§16-51A-2. Authorized access to and use of individualized investigational drugs, biological products, or devices.

(a) A manufacturer operating within an eligible facility and in accordance with all applicable federal law may make available to an eligible patient, and an eligible patient may request, the manufacturer's individualized investigational drug, biological product, or device from an eligible facility or manufacturer operating within an eligible facility. However, nothing in this article shall be construed to require a manufacturer of an individualized investigational drug, biological product, or device to make such individualized investigational drug, biological product, or device available to an eligible patient.

(b) A manufacturer of an individualized investigational drug, biological product, or device may provide the individualized investigational drug, biological product, or device to an eligible patient without receiving compensation or may require the eligible patient to pay the costs of, or the costs associated with, the manufacture of the individualized investigational drug, biological product, or device.

§16-51A-3. No liability to heirs for outstanding debt related to use of individualized investigational drugs, biological products, or devices.

If an eligible patient dies while being treated with an individualized investigational drug, biological product, or device, the eligible patient's heirs are not liable for any outstanding debt related to the treatment, including any costs attributed to lack of insurance coverage for the treatment.

§16-51A-4. Sanctions against health care providers prohibited.

(a) A licensing board shall not revoke, fail to renew, suspend, or take any other disciplinary action against a health care provider licensed under §30-1-1 et seq. of this code, based solely on the health care provider's recommendations to an eligible patient regarding access to or treatment with an individualized investigational drug, biological product, or device.

(b) An entity responsible for Medicare certification shall not take action against a health care provider's Medicare certification based solely on the health care provider's recommendation that a patient have access to an individualized investigational drug, biological product, or device.

§16-51A-5. Prohibited conduct by state officials.

No official, employee, or agent of this state shall block or attempt to block an eligible patient's access to an individualized investigational drug, biological product, or device. Counseling, advice, or a recommendation consistent with medical standards of care from a licensed health care provider, or denial of coverage by the Medicaid program do not constitute a violation of this article.

§16-51A-6. No private right of action against manufacturers of individualized investigational drugs, biological products, or devices.

No private right of action may be brought against a manufacturer of an individualized investigational drug, biological product, or device, or against any other person or entity involved in the care of an eligible patient using an individualized investigational drug, biological product, or device, for any harm caused to the eligible patient resulting from use of the individualized investigational drug, biological product, or device as long as the manufacturer or other person or entity has made a good-faith effort to comply with the provisions of this article and has exercised reasonable care in actions undertaken pursuant to this article.

§16-51A-7. Insurance coverage of clinical trials.

Nothing in this article shall be construed to affect a health benefit plan's obligation to provide coverage for an insured's participation in a clinical trial as set forth in §33-1-1 et seq. of this code.

§16-51A-8. Effective Date.

The provisions of this article are effective on January 1, 2026.

NOTE: The purpose of this bill is to permit access to individualized treatments for eligible patients.

Strike-throughs indicate language that would be stricken from a heading or the present law and underscoring indicates new language that would be added.

Print On Demand

Volver al texto completo